The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age

INTRODUCTION: Interleukin-1 (IL-1) blockade is the treatment of choice of cryopyrin associated periodic syndromes (CAPS). Anti-IL-1 monoclonal antibody (canakinumab) was recently registered. However no clear data are available on the optimal schedule of administration of this drug. The aim of the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Caorsi, Roberta, Lepore, Loredana, Zulian, Francesco, Alessio, Maria, Stabile, Achille, Insalaco, Antonella, Finetti, Martina, Battagliese, Antonella, Martini, Giorgia, Bibalo, Chiara, Martini, Alberto, Gattorno, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672768/
https://www.ncbi.nlm.nih.gov/pubmed/23442610
http://dx.doi.org/10.1186/ar4184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672768/
https://www.ncbi.nlm.nih.gov/pubmed/23442610
http://dx.doi.org/10.1186/ar4184

Ejemplares similares